Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337018 | 0.92 | DHODH (0.48) | DHODHPTGER4POLBBCL2GAA | |
| SCHEMBL2595448 | 0.86 | POLB (0.48) | DHODHPTGER4POLBBCL2GAA | |
| SCHEMBL1337628 | 0.85 | AKR1C2 (0.55) | DHODHPOLBGAAL3MBTL1HTT | |
| SCHEMBL15928790 | 0.84 | MEN1 (0.59) | DHODHPTGER4POLBL3MBTL1KMT2A | |
| SCHEMBL1336975 | 0.83 | DHODH (0.79) | DHODHGAAL3MBTL1 | |
| SCHEMBL1337577 | 0.83 | DHODH (0.53) | DHODHPTGER4POLBGAAL3MBTL1 | |
| SCHEMBL12127685 | 0.82 | DHODH (0.46) | DHODHPTGER4BCL2HTTSMN1; SMN2 | |
| SCHEMBL1337715 | 0.82 | DHODH (0.62) | DHODH | |
| SCHEMBL1337640 | 0.81 | BCL2 (0.58) | DHODHBCL2SMN1; SMN2KMT2A | |
| SCHEMBL1337621 | 0.81 | DHODH (0.51) | DHODHPTGER4POLBGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | claimed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | claimed |
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | INCOZEN THERAPEUTICS PVT. LTD. (CH) | 2014-08-07 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | RHIZEN PHARMACEUTICALS SA (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220050-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885PTGER4 1882/4885POLB 1683/4885 |
| US-20110275603-A1 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS | DHODH, DLD, DHFR | DHODH 1/4885PTGER4 1882/4885POLB 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.